@article {Shabrawishi2020.05.08.20095679, author = {Mohammed Hassan Shabrawishi and Abdallah Y Naser and Hassan Alwafi and Ahmad Mansoor Aldobyany and Abdelfattah Ahmed Touman}, title = {Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions}, elocation-id = {2020.05.08.20095679}, year = {2020}, doi = {10.1101/2020.05.08.20095679}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {BACKGROUND Despite lack of convincing evidence of the efficacy of hydroxychloroquine, it has been suggested to be used for the treatment of SARS-CoV-2 to accelerate the negative virus conversion. We aimed to explore the association between negative nasopharyngeal SARS-CoV-2 PCR clearance and different therapeutic interventions.METHODOLOGY This was a retrospective cohort study of 93 patients who were admitted to medical ward with a PCR confirmed diagnosis of COVID-19 and met the inclusion criteria in a tertiary hospital in Mecca, Saudi Arabia. There were three interventional subgroups (group A (n=45): who received antimalarial drug only classified as (A1), combined with azithromycin (A2) or combined with antiviral drugs (A3)), and one supportive care group (group B) (n=48). The primary and secondary endpoints of the study were achieving negative SARS-CoV-2 nasopharyngeal PCR sample within five days or less from the start of the intervention and 12 days or less from the diagnose, respectively.RESULTS The mean age of the patients was 43.9 years (SD:15.9). A median time of 3.00 days (IQR:2.00-6.50) needed from the time of starting the intervention/supportive care to the first negative PCR sample. There was no statistically significant difference neither between the percentage of patients in the interventional group and the supportive care group who achieved the primary or the secondary endpoint, nor in the median time needed to achieve the first negative PCR sample (p\>0.05).CONCLUSION Prescribing antimalarial medications was not shown to shorten the disease course nor to accelerate the negative PCR conversion rate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.}, URL = {https://www.medrxiv.org/content/early/2020/05/11/2020.05.08.20095679}, eprint = {https://www.medrxiv.org/content/early/2020/05/11/2020.05.08.20095679.full.pdf}, journal = {medRxiv} }